Exelixis (EXEL) Total Debt (2010 - 2017)
Exelixis (EXEL) recorded quarterly Total Debt of $113.3 million in Q1 2017, up 3.87% quarter-over-quarter from $109.1 million in Q4 2016, and up 5.44% on a YoY basis from $107.5 million in Q1 2016.
Exelixis (EXEL) Total Debt (2010 - 2017) Analysis & Trends
Exelixis' Total Debt history runs 8 years deep, the most recent figure standing at $113.3 million for Q1 2017.
- In Q1 2017, Total Debt rose 5.44% year-over-year to $113.3 million; the TTM figure through Mar 2017 stood at $113.3 million (up 5.44% YoY), while the FY2016 annual figure was $109.1 million, up 36.4% from the prior year.
- Total Debt was $113.3 million for Q1 2017 at Exelixis, up from $109.1 million in the prior quarter.
- In the past five years, Total Debt ranged from a high of $177.4 million in Q4 2014 to a low of $27.5 million in Q2 2016.
- Historically, Total Debt has averaged $99.0 million across 5 years, with a median of $90.8 million in 2013.
- The sharpest annual moves came in 2014 and 2016: Total Debt soared 96.45% in 2014, then slumped 65.62% in 2016.
- A 5-year view of Total Debt shows it stood at $90.3 million in 2013, then jumped by 96.45% to $177.4 million in 2014, then sank by 54.92% to $80.0 million in 2015, then surged by 36.4% to $109.1 million in 2016, then grew by 3.87% to $113.3 million in 2017.
- The last three Total Debt figures came in at $113.3 million (Q1 2017), $109.1 million (Q4 2016), and $29.4 million (Q3 2016), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Debt (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 719,706.53 Bn | 719,706.50 Bn | - | - |
| 2 | Belite Bio | 55,800.00 Bn | 55,800.00 Bn | - | - |
| 3 | Quantum Biopharma | 18,182.30 Bn | 18,182.29 Bn | - | - |
| 4 | Legend Biotech | 3,154.00 Bn | 3,153.71 Bn | 242.10 Mn | 319.10 Mn |
| 5 | Akari Therapeutics | 1,844.30 Bn | 1,844.29 Bn | - | - |
| 6 | Evaxion A | 1,567.96 Bn | 1,567.94 Bn | - | - |
| 7 | Psyence Biomedical | 251.43 Bn | 251.42 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 112.56 Bn | 105.31 Bn | 2.59 Bn | - |
| 9 | Abivax | 94.37 Bn | 94.37 Bn | - | - |
| 10 | Exelixis | 13.37 Bn | 12.59 Bn | 590.86 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2017 | 113.35 Mn |
| Dec 30, 2016 | 109.12 Mn |
| Sep 30, 2016 | 29.37 Mn |
| Jun 30, 2016 | 27.50 Mn |
| Mar 31, 2016 | 107.50 Mn |
| Dec 31, 2015 | 80.00 Mn |
| Sep 30, 2015 | 80.45 Mn |
| Jun 30, 2015 | 80.00 Mn |
| Mar 31, 2015 | 83.91 Mn |
| Dec 31, 2014 | 177.45 Mn |
| Sep 30, 2014 | 176.50 Mn |
| Jun 30, 2014 | 174.26 Mn |
| Mar 31, 2014 | 80.22 Mn |
| Dec 31, 2013 | 90.33 Mn |
| Sep 30, 2013 | 90.76 Mn |
| Jun 30, 2013 | 91.13 Mn |
| Mar 31, 2013 | 91.61 Mn |
| Dec 31, 2012 | 92.09 Mn |
| Sep 30, 2012 | 92.89 Mn |
| Jun 30, 2012 | 93.68 Mn |